Comparison of immunogenic properties of native and inactivated Mannheimia haemolytica Lkt in calves

• Autorzy: Wernicki A. , Mikucki P. , Urban-Chmiel R. , Puchalski A.
• Języki publikacji: EN

Abstrakty

EN

The aim of this study was to compare the immunostimulatory properties of Lkt of M. haemolytica inactivated by formaldehyde and glutaraldehyde and to evaluate the neutralizing properties of anti-Lkt antibodies. The experiment was conducted on 20 Black-and-White Lowland calves of 100 kg body weight, assigned to 4 experimental groups. The animals were given subcutaneous vaccine injections with native Lkt, Lkt inactivated by formaldehyde or Lkt inactivated by glutaraldehyde. The anti-Lkt antibody titres were measured using an enzyme-linked immunosorbent assay (ELISA), based on absorb- ance of the sera obtained from the animals immunized with the different forms of Lkt. The protective effects of the antibodies present in the sera isolated from the vaccinated animals were estimated using an MIT assay. Analysis of the ELISA absorbance values in the sera from calves in the vaccinated groups did not show any significant differences between the groups. The highest increase in absorbance of sera was observed in calves from the group that received formaldehyde-inactivated Lkt. In the case of calves immunized with native Lkt, the absorbance values were lower than in the group immunized with Lkt inactivated by formaldehyde. The lowest absorbance values were observed in sera obtained from calves vaccinated with Lkt inactivated by glutaraldehyde. Analysis of the MTT assay results revealed the greatest Lkt-neutralizing properties of antibodies in the sera of calves immunized with two doses of a vaccine containing native Lkt and Lkt inactivated with formaldehyde.

Słowa kluczowe

EN

calf; animal disease; bacterial agent; bovine pneumonic pasteurellosis; A1 serotype; Mannheimia haemolytica; respiratory syndrome; leukotoxin; immunization; immunogenic property; ELISA test; antibody; vaccination

• Wydawca: -
• Czasopismo: Polish Journal of Veterinary Sciences
• Rocznik: 2008
• Tom: 11
• Numer: 2
• Strony: 83-88
• Opis fizyczny: p.83-88,fig.,ref.

Twórcy

autor

Wernicki A.

• University of Life Sciences in Lublin, Akademicka 12, 20-033 Lublin, Poland

autor

Mikucki P.

autor

Urban-Chmiel R.

autor

Puchalski A.

Bibliografia

• Bowersock L, Waleed W, Shalaby L, Levy M, Samules M, Lallone R, White M, Borie D, Lehmeyer J, Park K (1994) Evaluation of an administered vaccine using hydrogels containing bacterial exotoxins of Pcisteurella haemolytica, in cattle. Am J Vet Res 55: 500-509. Clinkenbeard KD, Upton ML (1991) Lysis of bovine plate­lets by Pasteurella haemolytica leukotoxin. Am J Vet Res 52: 453-457.
• Clinkenbeard K, Clinkenbeard C, Waurzyniak B (1995) Choatropic agents cause disaggregation and enhanced activity of P. haemolytica leukotoxin. Vet Microbiol 45: 201-209.
• Confer AW (1993) Immunogens of Pasteurella. Vet. Micro­biol 37: 353-368.
• Confer AW, Clinkenbeard KD, Gatewood DM, Driskel BA, Montelongo M (1997) Serum antibody responses of cattle vaccinated with partially purified native P. haemolytica leukotoxin. Vaccine 15: 1423-1429.
• Confer AW, Ayalew S, Panciera RJ, Montelongo M, Whith- worth LC, Hammer JD (2003) Immunogenicity of rec­ombinant Mannheimia haemolytica serotype 1 outer membrane protein PlpE and augmentation of a commer­cial vaccine. Vaccine 21: 2821-2829.
• Donachie W (1992) Prevention of pasteurellosis. Br Vet J 148: 93-5.
• Fowler S, Byron O, Jumel K, Xing D, Corbel M, Bolgiano B (2003) Novel configurations of high molecular weight species of the pertussis toxin vaccine component. Vaccine 21: 2678-2688.
• Hughes HP, Campos M, Potter AA, Babiuk LA (1992) Mol­ecular chimerization of Pasteurella haemolytica leukotoxin to interleukin-2: effects on cytokine and anti­gen function. Infect Immun 60: 565-570.
• Hulskotte E, Dings M, Norley S, Osterhaus A (1997) Chemical inactivation of recombinant vaccinia viruses and the effects on antigenicity and immunogenicity of recombinant simian immunodeficiency virus envelope glycoproteins. Vaccine 15: 1839-1845.
• Jalava K, Hensel A, Szostak M, Resch S, Lubitz W (2002) Bacterial ghosts as vaccine candidates for veterinary ap­plications. J Control Release 85: 17-25.
• Kraabel BJ, Miller MW, Conlon JA, MacNeil HJ (1998) Evaluation of multivalent Pasteurella haemolytica vaccine in bighorn sheep: protection from experimental chal­lenge. J Wild Dis 34: 325-333.
• Le Buanec H, Bizzini B (2000) Procedures for preparing biologically inactive, but immunogenic HIV-1 Tat protein (Tat Toxoid) for human use. Biomed Pharmacother 54: 41-44.
• Manetti R, Massari P, Marchetti M, Magagnoli C, Nuti S, Lupetti P, Ghiara P, Rappuoli R, Telford J (1997) De­toxification of the Helicobacter pylori cytotoxin. Infect Im­mun 65: 4615-4619.
• Metz B, Jiskoot W, Hennink WE, Crommelin DJ, Kersten GF (2003) Physicochemical and immunochemical tech­niques predict the quality of diphtheria toxoid vaccines. Vaccine 22: 156-167.
• Mikucki P, Wernicki A, Puchalski A, Urban-Chmiel R (2006) Using native and inactivated leukotoxin Man­nheimia haemolytica in specific immunoprophylaxis of sheep’s respiratory syndrome. Med Weter 62: 1302- -1306.
• Odendaal MW, Morris S, Preez E, Aitchison H (1997) The humoral immune response in cattle after immunization with a multivalent lBRfPl-3/Pasteurella haemolytica Al leukotoxin vaccine. Onderst J Vet Res 64: 205-216.
• Petras SF, Chidambaram M, Illyes E, Froshauer S, Wein- stock GM, Reese C (1995) Antigenic and virulence prop­erties of Pasteurella haemolytica leukotoxin mutants. In­fect Immun 63: 1033-1039.
• Petre J, Pizza M, Nencioni L, Podda A, De Magistris M, Rappuoli R (1996) The reaction of bacterial toxins with formaldehyde and its use for antigen stabilization. Dev Biol Stand 87: 125-134.
• Shewen PE, Wilkie BN (1983) Pasteurella haemolytica cytotoxin: Production by recognized serotypes and neu-tralization by type-specific rabbit antisera. Am J Vet Res 44: 715-719.
• Srinand S, Ames T, Werdin R, Yoo S, Maheswaran S (1996a) Evaluation of three experimental subunit vac­cines against pneumonic pasteurellosis in cattle. Vaccine 14: 147-154.
• Srinand S, Maheswaran SK, Ames TR, Werdin R, Hsuan S (1996b) Evaluation of efficacy of three commercial vaccines against experimental bovine pneumonic pas­teurellosis. Vet Microbiol 52: 81-89.
• Sutherland AD (1988) A rapid micro-method for the study of antibody-mediated killing of bacteria, with specific ap­plication to infection of sheep with Pasteurella haemolytica. Vet Microbiol 16: 263-271.
• Thumbikat P, Briggs R, Kannan M, Maheswaran S (2003) Biological effects of two genetically defined leukotoxin mutants of Mannheimia haemolytica. Microb Pathog 34: 217-226.
• Tori Y, Tokumaru Y, Kawaguchi S, Izumi N, Maruyama S, Mukamoto M, Kozaki S, Takahashi M (2002) Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid. Vaccine 20: 2556-2561.
• Urban-Chmiel R, Wernicki A, Puchalski A, Mikucki P (2004) Evaluation of Mannheimia haemolytica leukotoxin prepared in nonsupplemented and BSA or FBS supplemented RPMI 1640 medium. Pol J Vet Sei 7: 1-8.
• Vega MV, Maheswaran SK, Leininger JR, Ames TR (1987) Adaptation of colorimetric microtitration assay for quan­tifying Pasteurella haemolytica A1 leukotoxin and anti- leukotoxin. Am J Vet Res 48: 1559-1564.
• Ward AC, Hunter DL, Rudolph K, DeLong W, Bulgin J, Cowan L, McNeil H, Miller MW (1999) Immunologic responses of domestic and bighorn sheep to a multivalent Pasteurella haemolytica vaccine. J Wild Dis 35: 285-296.
• Wernicki A, Urban-Chmiel R, Puchalski A, Mikucki P (2001) Utilization of leukotoxin as vaccine antigen in immunoprophylaxis of shipping fever in cattle. Pol J Vet Sei 4: 193-198.
• Wernicki A, Puchalski A, Urban-Chmiel R, Mikucki P (2002) Estimation of humoral immunological response in calves to antigens Mannheimia haemolytica serotype 1 outer membrane proteins (OMPs). Med Weter 58: 860-862.
• Winsnes R, Hendiksen C, Sesardic D, Akkermans A, Daas A (1999) Serological assays as alternatives to Ph Eur Challenge test for batch release of tetanus vaccines for human use. Dev Biol Stand 101: 277-288.